Bal Pharma (BOM:524824) Cyclically Adjusted Revenue per Share: ₹223.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524824 Bal Pharma Ltd BOM:524824
66 GF Score
Price ₹84.67
GF Value ₹103.90
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Bal Pharma Cyclically Adjusted Revenue per Share?

Bal Pharma BOM:524824 +0.21% 66 Cyclically Adjusted Revenue per Share is ₹223.35 as of Jun. 2026. GuruFocus rates BOM:524824 with a GF Score™ of 66/100 and a GF Value™ of ₹103.90 (Modestly Undervalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bal Pharma's adjusted revenue per share for the three months ended in Jun. 2026 was ₹56.001. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹223.35 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Bal Pharma's average Cyclically Adjusted Revenue Growth Rate was 1.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bal Pharma was 3.10% per year. The lowest was 0.60% per year. And the median was 1.30% per year.

As of today (2026-08-31), Bal Pharma's current stock price is ₹84.67. Bal Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹223.35. Bal Pharma's Cyclically Adjusted PS Ratio of today is 0.38.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bal Pharma was 0.66. The lowest was 0.27. And the median was 0.45.


Bal Pharma  (BOM:524824) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bal Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=84.67/223.35
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bal Pharma was 0.66. The lowest was 0.27. And the median was 0.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bal Pharma Cyclically Adjusted Revenue per Share Related Terms


Bal Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bal Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bal Pharma Cyclically Adjusted Revenue per Share Chart

Bal Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 210.80 216.45 220.57 218.90 220.56

Bal Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 219.83 220.58 220.94 220.56 223.35

BOM:524824 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bal Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bal Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bal Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bal Pharma's Cyclically Adjusted PS Ratio falls into.


BOM:524824
66GF Score
Bal Pharma Ltd BOM:524824
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bal Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bal Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=56.001/167.3573*167.3573
=56.001

Current CPI (Jun. 2026) = 167.3573.

Bal Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 39.095 102.901 63.584
201603 42.583 102.518 69.515
201606 31.484 105.961 49.727
201609 46.748 105.961 73.835
201612 41.491 105.196 66.008
201703 45.452 105.196 72.310
201803 41.566 109.786 63.363
201806 37.876 111.317 56.944
201809 40.373 115.142 58.682
201812 37.876 115.142 55.052
201903 34.972 118.202 49.515
201906 34.619 120.880 47.930
201909 31.652 123.175 43.005
201912 30.463 126.235 40.387
202003 21.417 124.705 28.742
202006 37.005 127.000 48.764
202009 45.636 130.118 58.697
202012 55.674 130.889 71.186
202103 45.670 131.771 58.004
202106 46.812 134.084 58.428
202109 47.241 135.847 58.199
202112 46.665 138.161 56.526
202203 54.942 138.822 66.236
202206 45.941 142.347 54.013
202209 46.201 144.661 53.450
202212 50.644 145.763 58.147
202303 46.397 146.865 52.871
202306 50.098 150.280 55.791
202309 60.672 151.492 67.026
202312 49.610 152.924 54.292
202403 53.168 153.035 58.144
202406 45.917 155.789 49.327
202409 45.975 157.882 48.734
202412 50.168 158.323 53.031
202503 51.237 157.552 54.426
202506 42.687 159.755 44.718
202509 46.949 162.289 48.415
202512 55.179 163.281 56.557
202603 52.878 164.272 53.871
202606 56.001 167.357 56.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹223.35 mean?
Bal Pharma (BOM:524824) has a Cyclically Adjusted Revenue per Share of ₹223.35 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bal Pharma and its competitors.
Is Bal Pharma's Cyclically Adjusted Revenue per Share too high?
Bal Pharma's current Cyclically Adjusted Revenue per Share is ₹223.35. Overall, Bal Pharma has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bal Pharma's Cyclically Adjusted Revenue per Share compare to ZTS?
Bal Pharma's Cyclically Adjusted Revenue per Share of ₹223.35 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bal Pharma and its competitors. Bal Pharma's current Cyclically Adjusted Revenue per Share is ₹223.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bal Pharma (BOM:524824) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹103.90, compared to a current price of ₹84.67 — trading 18.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹223.35. Bal Pharma's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bal Pharma (BOM:524824), the current Cyclically Adjusted Revenue per Share is ₹223.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bal Pharma (BOM:524824) Overvalued in 2026?

Based on GuruFocus' analysis, Bal Pharma stock appears to be undervalued. The current stock price of ₹84.67 is trading 18.5% below its estimated GF Value™ of ₹103.90. GuruFocus considers Bal Pharma to be Modestly Undervalued.

Key valuation signals for BOM:524824:

  • Cyclically Adjusted Revenue per Share: ₹223.35
  • GF Value™: ₹103.90 vs. price of ₹84.67 (18.5% below fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the BOM:524824 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bal Pharma Business Description

Other Exchanges BALPHARMA:India
Address 10/1, Palace Road, 5th Floor, Lakshmi Narayan Complex, Bengaluru, KA, IND, 560052
Bal Pharma Ltd is a pharmaceutical company. It is principally engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients. The company specializes in prescription drugs, generic and over-the-counter products, intravenous infusion, and bulk actives.
66GF Score

Get the complete analysis for BOM:524824

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹84.67
Price
₹103.90
GF Value